Personalizing cancer medicine depends on the implementation of personalized diagnostics and therapeutics. Detailed genomic
screening is likely to play a central role in this.

Personalized Medicine has been widely depicted as a striking innovation, that is able to reform the standard approach to disease
management, replacing the one-size-fits-all scheme of medicine with a single-patient-sized medical intervention. Personalized
medicine promoters usually highlight its potential to combine a more effective health-care with costs containment, according
to the following rules:
monitoring of disease risks and more effective prevention;
• early intervention;
• selection of optimal therapy;
• reduction of trial-and-error prescribing and reduction of adverse drug reactions;
• exclusion of unnecessary drugs;
• therapeutic drug monitoring and disease progression/remission monitoring;
• increased patient compliance with therapy.

But, despite expectations, many unsolved practical issues, from technical and scientific to ethical, legal and economic topics,
are slowing down the translation of personalized medicine principles into medical practice. Furthermore, wide adoption of
personalized strategies also has to deal with the peculiar rules, policy and reimbursement system of each country. Application
of Personalized Medicine in the real world seems entangled by the unmet need to develop evidence-based guidelines.